CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa
Open Access
- 21 March 2006
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 6 (1), 59
- https://doi.org/10.1186/1471-2334-6-59
Abstract
Patients accessing antiretroviral treatment (ART) programmes in sub-Saharan Africa frequently have very advanced immunodeficiency. Previous data suggest that such patients may have diminished capacity for CD4 cell count recovery. Rates of CD4 cell increase were determined over 48 weeks among ART-naïve individuals (n = 596) commencing ART in a South African community-based ART programme. The CD4 cell count increased from a median of 97 cells/μl at baseline to 261 cells/μl at 48 weeks and the proportion of patients with a CD4 cell count <100 cells/μl decreased from 51% at baseline to just 4% at 48 weeks. A rapid first phase of recovery (0–16 weeks, median rate = 25.5 cells/μl/month) was followed by a slower second phase (16–48 weeks, median rate = 7.7 cells/μl/month). Compared to patients with higher baseline counts, multivariate analysis showed that those with baseline CD4 counts 500 cells/μl at 48 weeks, 19% had baseline CD4 cell counts <50 cells/μl. However, the proportion of these patients that attained a CD4 count 200 cells/μl at 48 weeks was lower than those with higher baseline CD4 cell counts. Patients in this cohort with baseline CD4 cell counts <50 cells/μl have equivalent or greater capacity for immunological recovery during 48 weeks of ART compared to those with higher baseline CD4 cell counts. However, their CD4 counts remain <200 cells/μl for a longer period, potentially increasing their risk of morbidity and mortality in the first year of ART.Keywords
This publication has 27 references indexed in Scilit:
- How can earlier entry of patients into antiretroviral programs in low-income countries be promoted?Clinical Infectious Diseases, 2006
- Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohortAIDS, 2005
- Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral TherapyClinical Infectious Diseases, 2005
- Rolling out antiretrovirals in Africa: there are still challenges ahead.Clinical Infectious Diseases, 2005
- Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Incomplete Immune Reconstitution after Initiation of Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients with Severe CD4+Cell DepletionThe Journal of Infectious Diseases, 2003
- Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infectionAIDS, 2003
- Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte dʼIvoireAIDS, 2003
- Predictors of Long‐Term Increase in CD4+Cell Counts in Human Immunodeficiency Virus–Infected Patients Receiving a Protease Inhibitor–Containing Antiretroviral RegimenThe Journal of Infectious Diseases, 2002
- Risk Factors for Developing Tuberculosis in HIV-1–Infected Adults From Communities With a Low or Very High Incidence of TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000